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Background/Aims
Endoscopic therapy for esophageal varices may lead to esophageal dysmotility. High-resolution manometry is probably the more 
adequate tool to measure esophageal motility in these patients. This study aimed to evaluate esophageal motility using high resolution 
manometry following eradication of esophageal varices by endoscopic sclerotherapy.
Methods
We studied 21 patients (11 women, age 52 [45-59] years). All patients underwent eradication of esophageal varices with endoscopic 
sclerotherapy and subsequent high resolution manometry. 
Results
A significant percentage of defective lower esophageal sphincter (basal pressure 14.3 [8.0-20.0] mmHg; 43% hypertonic) and 
hypocontractility (distal esophageal amplitude 50 [31-64] mmHg; proximal esophageal amplitude 40 [31-61] mmHg; distal contractile 
integral 617 [403-920] mmHg∙sec∙cm; 48% ineffective) was noticed. Lower sphincter basal pressure and esophageal amplitude 
correlated inversely with the number of sessions (P < 0.001). No manometric parameter correlated with symptoms or interval 
between last endoscopy and manometry. 
Conclusions
Esophageal motility after endoscopic sclerotherapy is characterized by: (1) defective lower sphincter and (2) defective and hypotensive 
peristalsis. Esophageal dysmotility is associated to an increased number of endoscopic sessions, but manometric parameters do not 
predict symptoms. 
(J Neurogastroenterol Motil 2016;22:226-230)
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Introduction  
Esophageal varices are secondary to portal hypertension due to 
the presence of a peri-esophageal portosystemic collateral circula-
tion.1 Although liver transplantation and trans-jugular intrahepatic 
portosystemic stent-shunts (TIPSS) are established methods to 
treat portal hypertension and consequently esophageal varices, dif-
ferent forms of endoscopic therapy have long been used for variceal 
bleeding prophylaxis and therapy.2 
227
Esophageal Motility After Sclerotherapy
Vol. 22, No. 2   April, 2016 (226-230)
Endoscopic therapy for esophageal varices may lead to esopha-
geal dysmotility due to the process of scarring. Previous reports 
focused on the alteration of esophageal motility after endoscopic 
therapy.3-13 These studies, however, relied on conventional manom-
etry for the evaluation. High-resolution manometry (HRM) is 
probably a more adequate tool to measure esophageal motility in 
these patients. HRM allows a sophisticated evaluation of the lower 
esophageal sphincter (LES) relaxation and of segmental peristal-
tic defects since altered peristalsis may occur only at the injection 
point.14
This study aimed to evaluate esophageal motility using HRM 
following eradication of esophageal varices by endoscopic sclero-
therapy.
Materials and Methods  
We studied 21 consecutive patients who had undergone esoph-
ageal variceal eradication by endoscopic sclerotherapy in the past 
and volunteered for the prospective evaluation of esophageal func-
tion (11 women, mean age 52 [45-59] years). 
Patients with previous foregut surgery, moderate or severe asci-
tes, primary esophageal motility disorders, or systemic diseases that 
affect esophageal motility were not recruited to the study.
Symptoms
Patients were questioned about dysphagia and esophageal 
symptoms of gastroesophageal reflux disease at the time of the 
HRM. Symptoms were considered positive if dysphagia occurred 
at least weakly for any type of food and heartburn or regurgitation 
occurred at least weekly. 
Endoscopic Therapy
All patients had variceal bleeding in the past and had medium 
of large size varices. Monthly endoscopic intraluminal injection of 
2% ethanolamine oleate was performed in all patients until eradica-
tion. The sclerosant volume injected varied from 3 mL to 18 mL 
with a median of 9 mL, and decreasing doses for progressive ses-
sions.15
The median number of sessions was 6 (4-10). The interval be-
tween the final sclerotherapy session and the esophageal manometry 
was 25 (12-94) months.
High-resolution Manometry 
 HRM was performed as previously described.16 In summary, 
patients fasted for at least 8 hours and discontinued any medications 
that interfered with esophageal and gastric motility 3 days before the 
study. A solid-state catheter with 36 circumferential sensors spaced 
1 cm was used (Medtronics, Los Angeles, CA, USA). The test 
was performed and analyzed according to the manufacturer’s in-
structions and dedicated software. Ten wet swallows of 5 mL water 
boluses at 30-second intervals were offered to allow the recording 
of: (1) the position, pressure (defined as the mid-expiratory pres-
sure), relaxation (as defined by the integrated relaxation pressure), 
and length of the LES, (2) amplitude, duration and propagation of 
the peristaltic waves at 3 cm and 7 cm above the LES, and (3) seg-
mental defects of peristalsis based on visual analysis. 
The normal values considered in this study derived from the 
Chicago group per system manufacturer software. They were LES 
length > 2.7 cm, LES basal pressure 13-43 mmHg, LES residual 
pressure < 15 mmHg, distal esophageal amplitude (DEA; sensor 
located 3 cm above the upper border of the LES) 41-168 mmHg, 
and proximal esophageal amplitude (sensor located 7 cm above 
the upper border of the LES) 37-166 mmHg. Distal contractile 
integral (DCI) defined esophageal contractions as ineffective (failed 
+ weak) if < 800 mmHg∙sec∙cm or hypercontractile if > 8000 
mmHg∙sec∙cm and distal latency (sec) < 4.5 seconds defined a 
premature contraction.
Statistical Methods
Variables are expressed as median (interquartile range), as a 
non-normal distribution of the data was found by the Shapiro-Wilk 
test. Spearman correlation or Mann-Whitney tests were used when 
appropriated. A value of P was considered significant at the 0.05 
level.
Ethics
The study was approved by the Institutional Review Board. 
There are no conflicts of interest. The authors are responsible for 
the manuscript and no professional or ghost writers were hired.
Results  
HRM was feasible in all patients without any complications. 
Dysphagia was reported by 8 (38%) patients, and reflux symptoms 
were reported by 10 (48%) patients.
Lower Esophageal Sphincter
Manometric parameters for the LES are shown in our Table. 
A significant percentage of patients had a defective LES. LES 
lengths (total and abdominal) did not correlate with symptom pres-
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ence, number of sclerotherapy sessions, or interval between the 
manometry and the final session of sclerotherapy. LES basal pres-
sure correlated inversely with the number of sessions (P < 0.001) 
(Fig. 1), but did not correlate with dysphagia (P = 0.700), reflux 
symptoms (P = 0.500) or interval between the final session and the 
HRM (P = 0.100). LES relaxation did not correlate with dyspha-
gia (P = 0.600), reflux symptoms (P = 0.700), number of sessions 
(P = 0.200), or interval between the final session and the HRM (P 
= 0.300). 
Esophageal Body
Manometric parameters for the esophageal body are shown in 
our table. DEA correlated with the number of sessions (P < 0.001) 
(Fig. 1) but not with symptoms of dysphagia (P > 0.99) or reflux (P 
= 0.600) or interval between the final session and the HRM (P = 
0.400). Proximal esophageal amplitude showed similar results with 
a correlation with the number of sessions (P = 0.010) (Fig. 1) but 
not with symptoms (P > 0.99) and time from last endoscopic treat-
ment (P = 0.400). DCI defined ineffective peristalsis in almost half 
of the patients. DCI did not correlate with dysphagia (P > 0.99), 
reflux symptoms (P > 0.99), the number of sessions (P = 0.400), 
and time from last endoscopic treatment (P = 0.900). Distal laten-
cy did not correlate with dysphagia (P = 0.600), reflux symptoms (P 
= 0.600), the number of sessions (P = 0.500), and time from last 
endoscopic treatment (P = 0.600). Two (9%) patients had hyper-
contractile segments (Fig. 2). No patient presented with pathologic 
peristaltic gaps.
Discussion  
There is no clinical reason to suppose that portal hypertension 
per se or for that matter cirrhosis or schistosomiasis, 2 important 
causes of portal hypertension - lead to alteration in esophageal mo-
Table. Manometric Findings in Patients After Endoscopic Sclero-
therapy (n = 21)
LES basal pressure (median [IQR], mmHg)
     Hypotonic 
     Hypertonic
14.3 (8.0-20.0)
43%
0
LES residual pressure (median [IQR], mmHg)
     Abnormal relaxation 
4.8 (1.6-7.2)
  5%
LES length (median [IQR], cm)
     Short 
2.6 (2.3-3.2)
95%
LES abdominal length (median [IQR], cm) 1.7 (1.0-2.4)
Distal esophageal amplitude 
  (median [IQR], mmHg)
     Hypercontractility
     Hypocontractility
50 (31-64)
0
33%
Proximal esophageal amplitude 
  (median [IQR], mmHg)
     Hypercontractility
     Hypocontractility
40 (31-61)
0
38%
Distal contractile integral 
  (median [IQR], mmHg∙sec∙cm)
     Ineffective
     Hypercontractility
617 (403-920)
48%
0
Distal latency (median [IQR], sec)
     Premature
5.8 (4.6-7.2)
24%
LES, lower esophageal sphincter; IQR, interquartile range.
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Figure 1. Correlation between number of endoscopic sclerotherapy 
sessions and lower esophageal sphincter (LES) basal pressure, distal 
esophageal amplitude (DEA), and proximal esophageal amplitude 
(PEA).
Figure 2. Example of hypercontractile distal segments after endo-
scopic sclerotherapy for esophageal varices with a distal contractile 
integral = 2050 mmHg ∙ sec ∙ cm.
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tility unless a systemic disease is the etiology of the liver failure.17 In 
fact, there are no studies that have focused exclusively on the mano-
metric testing of these patients. Secondary manifestations of portal 
hypertension may, however, influence esophageal motility. The 
presence of ascites does not alter LES pressure18,19 but the presence 
of varices has been associated with decreased DEA for some20 al-
though questioned by others.10 
Endoscopic therapy for esophageal varices may affect esopha-
geal motility due to the development of esophageal fibrosis. Previ-
ous studies showed motility changes after injection sclerotherapy,3,9,10 
while others only noticed manometric changes if esophageal steno-
sis4 or dysphagia5 were present, or acutely after 24 hours following 
the injection.7 Studies on rubber band variceal ligation found no 
changes in esophageal motility compared to patients before endo-
scopic therapy or sclerotherapy21 apart from transitory increased 
body amplitude.8
The LES is at risk of fibrosis after endoscopic sclerotherapy 
since injections are usually performed close to the esophagogastric 
junction. Conventional manometry series are contradictory with 
regard to LES basal pressure after endoscopic therapy for varices. 
Some authors noticed a decrease in pressure3,10,13 while others did 
not show any changes.5-7 Our results showed a significant percent-
age of patients with hypotonic LES and a positive correlation 
between the number of sclerotherapy sessions and LES basal pres-
sure. In fact, Sharma et al13 showed not only the same results but 
also noticed that the degree of chronic inflammatory cell infiltrate 
and fibrosis parallels the number of sessions. There is no previous 
data on LES relaxation. We hypothesized that LES fibrosis would 
also impair its relaxation; however, our results did not support this 
idea even with the use of sophisticated analysis with the HRM pa-
rameter the integrated relaxation pressure.22
Even though sclerosing agents are injected into the distal 
esophagus only, the centrifuge blood flow may cause the agent to 
ascend and contribute to fibrosis of the proximal esophagus as well. 
Lower DEA3 and higher percentage of non-peristaltic waves3,5 has 
been reported after sclerotherapy in conventional manometry stud-
ies. HRM also showed a significant proportion of defective and 
hypotensive peristalsis, directly proportional to the number of endo-
scopic sessions. Hypercontractile segments on the distal esophagus 
were noticed in almost 10% of our patients. These segmental ab-
normalities were missed on the automated analysis and they would 
be, obviously, not diagnosed by conventional manometry.
Manometric parameters did not correlate with symptoms ex-
cept for dysphagia that occured more frequently in patients with a 
higher LES pressure irrespective of its relaxation.
The current study has some limitations. First, it included a 
low number of patients. Although the number of studied patients 
matches other similar studies, it is small since the esophageal func-
tion tests are not part of their care and they volunteered to the 
study irrespective of symptoms. Second, esophageal manometry 
was not performed before the beginning of the endoscopic sessions 
to allow a comparison as a control group. Although HRM was 
done prospectively, patients were recruited after retrospective en-
doscopic therapy. Thus, the duration between the final therapy and 
the HRM was not uniform. The strength of the study is the long 
follow up and the application of sophisticated methodology with 
HRM. 
In conclusion, our results showed that esophageal motility after 
endoscopic sclerotherapy for esophageal varices is characterized 
by: (1) defective LES and (2) defective and hypotensive peristal-
sis. Esophageal dysmotility is associated to an increased number 
of endoscopic sessions, but manometric parameters do not predict 
symptoms. The number of endoscopic sclerotherapy sessions must 
be minimized or switched to a more efficient method, such as rub-
ber band ligation.
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